Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder

Neurol Neuroimmunol Neuroinflamm. 2020 Feb 25;7(3):e683. doi: 10.1212/NXI.0000000000000683. Print 2020 May.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Age of Onset
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / pharmacology*
  • Aquaporin 4 / immunology*
  • Female
  • Humans
  • Immunoglobulin G
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / pharmacology*
  • Neuromyelitis Optica / drug therapy*
  • Neuromyelitis Optica / immunology*
  • Treatment Outcome
  • Young Adult

Substances

  • AQP4 protein, human
  • Antibodies, Monoclonal, Humanized
  • Aquaporin 4
  • Immunoglobulin G
  • Immunologic Factors
  • ofatumumab